Achieving depletion of regulatory T cells while sparing tumor-specific effector T cells has long remained an elusive goal of immunotherapy. A new study describing the development of an antibody to the cytokine receptor CD25 optimized to ensure depletion of regulatory T cells without blocking binding of the cytokine IL-2 will reinvigorate interest in this therapeutic avenue.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. J. Immunol. 155, 1151–1164 (1995).
Onizuka, S. et al. Cancer Res. 59, 3128–3133 (1999).
Woo, E. Y. et al. J. Immunol. 168, 4272–4276 (2002).
Shang, B., Liu, Y., Jiang, S. J. & Liu, Y. Sci. Rep. 5, 15179 (2015).
Solomon, I. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-00133-0 (2020).
Jacobs, J. F. et al. Clin. Cancer Res. 16, 5067–5078 (2010).
Rech, A. J. et al. Sci. Transl. Med. 4, 134ra162 (2012).
Thornton, A. M. & Shevach, E. M. J. Exp. Med. 188, 287–296 (1998).
Arce Vargas, F. et al. Immunity 46, 577–586 (2017).
van Elsas, A., Hurwitz, A. A. & Allison, J. P. J. Exp. Med. 190, 355–366 (1999).
Suntharalingam, G. et al. N. Engl. J. Med. 355, 1018–1028 (2006).
Loskog, A. et al. Leukemia 20, 1819–1828 (2006).
Rafiq, S. et al. Nat. Biotechnol. 36, 847–856 (2018).
The authors declare no competing interests.
About this article
Cite this article
Ellis, G.I., Riley, J.L. How to kill Treg cells for immunotherapy. Nat Cancer 1, 1134–1135 (2020). https://doi.org/10.1038/s43018-020-00155-8